SOA Wealth Advisors LLC. Buys 517 Shares of Solventum Corporation $SOLV

SOA Wealth Advisors LLC. increased its stake in shares of Solventum Corporation (NYSE:SOLV) by 1,397.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 554 shares of the company’s stock after acquiring an additional 517 shares during the quarter. SOA Wealth Advisors LLC.’s holdings in Solventum were worth $42,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Rossby Financial LCC bought a new position in Solventum during the first quarter worth $25,000. Strengthening Families & Communities LLC boosted its stake in Solventum by 376.8% during the first quarter. Strengthening Families & Communities LLC now owns 329 shares of the company’s stock worth $25,000 after acquiring an additional 260 shares in the last quarter. Hara Capital LLC bought a new position in Solventum during the first quarter worth $38,000. Smartleaf Asset Management LLC lifted its stake in shares of Solventum by 193.4% in the first quarter. Smartleaf Asset Management LLC now owns 534 shares of the company’s stock valued at $40,000 after buying an additional 352 shares in the last quarter. Finally, Costello Asset Management INC bought a new position in shares of Solventum in the first quarter valued at $42,000.

Solventum Stock Performance

NYSE SOLV opened at $74.03 on Friday. Solventum Corporation has a 52-week low of $60.70 and a 52-week high of $85.92. The company has a 50-day simple moving average of $72.80 and a 200 day simple moving average of $72.21. The company has a debt-to-equity ratio of 2.14, a quick ratio of 0.86 and a current ratio of 1.22. The company has a market capitalization of $12.84 billion, a PE ratio of 34.27, a price-to-earnings-growth ratio of 3.03 and a beta of 0.50.

Solventum (NYSE:SOLV) last posted its quarterly earnings data on Thursday, August 7th. The company reported $1.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.45 by $0.24. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The business had revenue of $2.16 billion during the quarter, compared to the consensus estimate of $2.12 billion. During the same quarter last year, the company posted $1.56 earnings per share. The firm’s quarterly revenue was up 3.8% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, research analysts predict that Solventum Corporation will post 6.58 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $94.00 price objective (up from $87.00) on shares of Solventum in a research note on Friday, August 8th. Zacks Research raised shares of Solventum from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 15th. Wells Fargo & Company raised their price objective on shares of Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a research note on Monday, September 15th. KeyCorp assumed coverage on shares of Solventum in a research note on Friday, June 6th. They issued a “sector weight” rating on the stock. Finally, Morgan Stanley raised shares of Solventum from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $80.00 to $103.00 in a research note on Tuesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Solventum presently has a consensus rating of “Hold” and an average target price of $84.60.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.